Hepatitis B

Hepatitis B


FOR EACH DISEASE, TRIO DEVELOPS A CUSTOM SOLUTION THAT CAPTURES PATIENT LEVEL DATA THROUGHOUT THE PATIENT JOURNEY, ALL IN REAL-TIME. TRIO’S COVERAGE INCLUDES APPROVED DRUG REGIMENS, PHYSICIANS AND PHARMACIES WITHOUT BIAS.

Data Elements


DEMOGRAPHICS

  • Diagnosis
  • Age
  • Gender
  • Race / Ethnicity
  • BMI
  • Height / Weight
  • Genotype
  • Fibrosis Score

LABS

  • CBC
  • ALT / AST
  • HBV Viral Load
  • Serum Creatinine
  • eGFR
  • HbA1c
  • HBeAg, HBeAb
  • APRI score
  • Bone Density

PRIOR HISTORY

  • Prior Treatment Status
  • Prior Treatment Regimen
  • Duration of Therapy
  • Reason for Failure
  • Prior Transplant
  • Smoking Status
  • Illicit Drug Use

COMORBIDS

  • HIV Coinfection
  • Anxiety
  • Depression
  • Hypertension
  • Diabetes
  • Chronic Kidney Disease
  • Hyperlipidemia
  • Hemodialysis

PROVIDERS

  • Type (Physician, NP, PA)
  • Specialty
  • Academic vs Community
  • Specialty Pharmacy

PAYERS

  • Type (Commercial, Medicare, Medicaid, Dual Eligible)
  • Payer Name
  • Self-Pay and Patient Assistance
  • Eligibility
  • Correct PA form
  • Denial Reason

PA TIMELINE

  • PA Submitted Date
  • Approval / Denial Date
  • Appeals Submitted

DISPENSING INFO

  • Current Treatment Regimen Rx
  • Intended Regimen
  • Actual Regimen
  • Duration
  • Dispensed Regimen
  • Gaps in Therapy

Publications


2019


Differential Tenofovir Alafenamide (TAF) Adoption in HBV-Infected Populations; Assessment of Care in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, Nezam Afdhal

Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019

Conference dates: November 08, 2019 - November 12, 2019


Longer-Term Experience with Tenofovir Alafenamide (TAF) in HBV-Infected Patients; Changes in eGFR, FIB-4, ALT, and HBV DNA Suppression

K. Rajender Reddy, Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, Nezam Afdhal

Poster Presented at: American Association for the Study of Liver Disease (AASLD) – The Liver Meeting 2019

Conference dates: November 08, 2019 - November 12, 2019


Clinical Practice Experience with Tenofovir Alafenamide (TAF) for Treatment of Hepatitis B in the US

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Janna Radtchenko, and Nezam Afdhal

Poster Presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Conference dates: May 18, 2019 - May 22, 2019


Effectiveness and Safety with Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz and Nezam Afdhal

Poster Presented at: The European Association for the Study of the Liver (EASL)

Conference dates: April 10, 2019 - April 14, 2019


Effectiveness and Safety with Tenefovir Alafenamide (TAF) for Hepatitis B in Patients of Asian Race in US Clinical Practice

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan, Keith Spitz and Nezam Afdhal

Oral Presented at: Asian Pacific Association for the Study of the Liver (APASL)

Conference dates: February 20, 2019 - February 24, 2019




2018


Treatment of Hepatitis B in the US: Real-World Evidence from the TRIO Network

Ho Bae, Michael Curry, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 09, 2018 - November 13, 2018


Early Adoption of Tenofovir Alafenamide (TAF) for Hepatitis B in US Clinical Practice: Real-World Evidence from the TRIO Network

Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K. Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Scott Milligan and Nezam Afdhal

Poster Presented at: The American Association for the Study of Liver Diseases (AASLD)

Conference dates: November 09, 2018 - November 13, 2018